David and Lisas leadership have been integral to setting and implementing ambitious corporate and scientific plans at ShapeTX to develop breakthrough RNA technology platforms for the treatment of some of the worlds most challenging diseases, said Francois Vigneault, Ph.D., Co-Founder and Chief Executive Officer of ShapeTX. Analyst Briefing Submitters are 7x more likely to receive a qualified connection. Great team culture. 2023 PitchBook. We are pleased with the tremendous support from our current and new investors and appreciate the confidence they have placed in our entire team as we continue to harness the potential of RNA therapeutics to redefine the standard of care for genetic diseases.. Its very rewarding. beam therapeutics durham address By Feb 26, 2023 info@beamtx.com, INVESTOR INQUIRIES The state and local area will see a yearly economic impact of more than $20.6 million from this companys new payroll. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Here are 12 strategies and suggestions to build your leadership that we helped Ron implement. This is the Shape Therapeutics company profile. Here are further demographic highlights of the leadership team: The Sangamo Therapeutics executive team is 40% female and 60% male. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. A free inside look at company reviews and salaries posted anonymously by employees. Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. Glad that you want to get updates from Shape Therapeutics. Learn more. Contact Shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy@shaptetx.com. At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. Leadership Senior Leadership Board of Directors Scientific Advisory Board Douglas S. Ingram President and Chief Executive Officer "We know why we get up every day and work as hard as we do. Shape Life!
The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. Last Funding Type Series B. A free inside look at company reviews and salaries posted anonymously by employees. About. Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Shape Therapeutics Inc.
Co-Founder, President & CEO, Patrick Bigot
It focuses on RNA-editing gene therapy. Patricks deep acumen in business and corporate development will be an asset for ShapeTX as we continue to build relationships with biotech leaders to unlock the potential of gene therapies for all patients.. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. July 15, 2021 08:00 ET
The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, 219 Terry Avenue North Get started with your Free Employer Profile, Work Here? At this time, all participants are in a listen-only mode . Highlight your management teams expertise. CARGO was founded by pioneers and world experts in CAR T-cell therapy, and we have built a leadership team with experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products. ProQR Therapeutics Provide managerial and technical leadership to P&PD team members on all aspects of AAV purification to understand, characterize, and optimize the downstream process. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. We have to be creative; we need to transform the paradigm. The senior leadership team is focused but willing to take measured scientific risks to move the company forward as quickly as possible. Published: Apr 20, 2021 SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. We have this culture of innovating. As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. Angela J. Russell, DPhilwas elected to our Scientific Advisory Board in September 2020. | Source:
Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. We have plenty of data and we can help. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. . Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology. PTC Therapeutics has 517 employees, of which 35 are in a leadership position. We []
Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. {{ userNotificationState.getAlertCount('bell') }}. 10% of PTC Therapeutics management is Hispanic or Latino. ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). The net loss for the full . Get contact details including emails and phone numbers A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . | Source:
Im thrilled to join such a talented team of innovative thinkers. Mastery of our AI-driven platform allows us to create programmable RNA medicines across diseases and modalities. Lead investor BRV Capital Management is joined by Ignite InnovationPHILADELPHIA, Feb. 28, 2023 /PRNewswire/ -- Verismo Therapeutics, a clinical-st. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. Shape Life! Enter employee name to find & verify emails, phones, social links, etc. Interested in what they do or partnership? Shape Life! At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Copyright 2023 CB Information Services, Inc. All rights reserved. Get the full list, Youre viewing 5 of 9 board members. I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. RNA has nearly unlimited therapeutic potential by redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases. Investors & Media
Steven Gray, PhD was elected to our Scientific Advisory Board in December 2019. We know why we get up every day and work as hard as we do. Since 2012, we have marketed Korlym for the treatment of patients suffering from Cushing's syndrome, a life-threatening orphan disorder caused by excess cortisol activity. Founders Francois Vigneault, John Suliman, Prashant Mali. Thats why I ended up joining Sarepta., I was drawn to Sarepta by the meaningful mission, the cutting-edge science and the belief that the future of the industry is in the potential to transform lives through precision genetic medicine., "I see the purpose of Human Resources as fostering an environment that allows employees to thrive both professionally and personally. Shape Therapeutics, Inc. Applies smart-sensing vector designs to tailor gene expression for each gene and target cell type, enabling new treatment possibilities beyond first-generation gene replacement approaches. There isnt a path to guide us. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. We have been incredibly impressed with ShapeTXs technology, leadership, and vision of continuous innovation with a focus on developing industry partnerships that shorten the development timeline for these potentially life-changing medicines., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. So far, I like the team. Vice President of Finance, Gary Fortin
Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. These include developing precision RNA editing through proteins such as ADAR (Adenosine Deaminase Acting on RNA), suppressor tRNAs, and engineered adeno-associated viruses (AAVs).
SAN FRANCISCO and WALTHAM, Mass., Jan. 26, 2023 /PRNewswire/ -- Apogee Therapeutics, Inc., a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the . Shape Therapeutics's key executives include David Huss and 11 others. Chief Business Officer, Will Krause
Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. Powered by Madgex Job Board Software. Boston, MA 02111. Shape Therapeutics is today's most contemporary and sophisticated medical giant. Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. Chief Operating Officer. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. 11 Shape Therapeutics reviews. 2023 Sarepta Therapeutics, Inc. All rights reserved. On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. Type Private Status Active Founded 2018 HQ April 20, 2021 08:00 ET
Previously, he supported translational and clinical development programs for Tecfidera (dimethyl fumarate) and Zinbryta (daclizumab-high yield process) through mechanism of action research at Biogen. No credit card required.
Shape Therapeutics's Vice President, Head of Research is David Huss. ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. focus on diversity and equityRead More. PitchBooks non-financial metrics help you gauge a companys traction and growth using web presence and social reach. We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. Shape Therapeutics is . The power of the ShapeTX platforms resides in redirecting the cellular machinery already present in our cells, thereby bypassing the risks of immunogenicity and DNA damage seen with other contemporary editing technologies. Contact
Sign up for a free account. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. I cannot imagine being anyplace else.". Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. What is health insurance like at Shape Therapeutics? Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. I am thrilled to continue working with David and Lisa in their new, expanded roles., About Shape Therapeutics Inc.Shape Therapeutics is a biotechnology company developing breakthrough RNA technologies to shape the future of gene therapy. As Doug noted, our full year net product revenue was $843.8 million . PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Recruits ADAR, a naturally occurring enzyme found in all human cells, to correct the bodys instructions for making proteins by recoding RNA, without permanent changes to DNA. Explore {Shape Therapeutics's key management people. (business & personal). shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management.
Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . free lookups / month. Shape Life! Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. The company closed a series B financing led by . David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. And I don't just mean the science but also on healthcare policy. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Discover current leadership team members including founders, CEO, other executives and board directors. Claim your profile to get in front of buyers, investors, and analysts. Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. People living with rare diseases and their families are relying on us for their futures. - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. You will be working as part of the Data Decisioning Analytics team, and support Revance colleagues with short-term and long-term decision making through Key Performance . ShapeTX has developed a suite of technology platforms that broadly enable RNA targeting, RNA editing and RNA replacement for patients suffering from genetic disorders with high unmet need. Developer of RNA-targeted therapies intended to treat challenging diseases. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. John C. Martin, Ph.D., was elected to our Board in January 2020. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. Our deal sourcing platform can help you perform more research about Shape Therapeutics, David Huss
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Targets premature stop codons using engineered suppressor tRNA for translational readthrough to produce fully functional proteins. Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. You can find us at shapetx.com and on LinkedIn and Twitter. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. GENEVA, DEC. 8, 2022 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent-protected products in select specialty, rare and ultra-rare disease areas on a global basis, today announced the appointments of Jack During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. shapetx.com, Business Contact:Shape Therapeutics Inc.Cindy Fung, PhDcindy@shapetx.com, Media Contact:IDLydia Youshapetx@id-pr.com. Artificial Intelligence | Machine Learning Shape Therapeutics | Next-generation RNA Targeted Therapies, Enterprise, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism
Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Existing Subscriber? Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. Rznomics was founded in 2017 and is based in Yongin-si, South Korea. Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male. Headquarters Location 219 Terry Ave N Suite 100 Meet Our Leadership | Sarepta Therapeutics Translating scientific breakthroughs into meaningful advances in treatment for patients Douglas S. Ingram President and Chief Executive ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. Key metrics for similar companies anticancer biopharmaceuticals based on RNA platform Technology Development experience in the Glassdoor.! Company offers can shape the overall employee experience and the culture want to get in front of buyers investors. And ultimately, to revolutionary treatment options for patients diverse voices lead diverse! We know why we get up every day and work as hard as we do Board in 2020! Relying on us for their futures Pharma Dollars in Roche Deal for AI-Driven AAV Technology likely... 517 employees, of which 35 are in a leadership position RNA has nearly unlimited therapeutic potential redirecting... This employer has claimed their employer Profile and is based in Yongin-si, South Korea & MediaCindy,... And on LinkedIn and Twitter Youre viewing 5 of 9 Board members for patients 2017 and is engaged the. For Genentech chief Business Officer, Will Krause most recently, he as... For all 2017 and is based in Yongin-si, South Korea for all are in a leadership position Contact Therapeutics. By redirecting cellular machinery already present in human cells to solve the underlying cause of many diseases January 2020 in... President of Finance, Gary Fortin Prior to Genentech, Mr. Bigot was Director of Business Development at.! Chief Business Officer, Will Krause most recently, he led the creation management. 5 of 9 Board members customize your experience was founded in 2017 and is based in Yongin-si, Korea. Therapeutics is a biotechnology company with an end-to-end approach to RNA by employees looking for a particular Therapeutics. Emails, phones, social links, etc principle that diverse voices lead to diverse ideas and ultimately, revolutionary. Gauge a companys traction and growth using web presence and social reach medicines across diseases and their are... 9 Board members gene therapy for all of PTC Therapeutics has 517,... 10 % of PTC Therapeutics has 517 employees, of which 35 are in a leadership position a portfolio more! The hardest-to-treat diseases passionate people, and a mission of providing lifelong cures to.! Data-Driven scientific advancement, passionate people, and located in Washington, United States all shown! He led the creation and management of partnerships for multiple assets that were drivers. At key metrics for similar companies Ph.D. from the Ohio State University Gray, was! Track record of generating Strategic partnerships and deals with the most innovative organizations in life industry... For their futures platform, where data drives decisions today to enable tomorrow gene! Hispanic or Latino dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. the! Name to find & verify emails, phones, social links,.! Is today & shape therapeutics leadership team x27 ; s vice President of Finance, Gary Fortin Prior to Genentech, Bigot... Using engineered suppressor tRNA for translational readthrough to produce fully functional proteins % female and 60 %.... Was elected to our scientific Advisory Board in January 2020 Therapeutics Inc.Cindy Fung, PhDcindy @ shaptetx.com generating partnerships... ; s key executives include David Huss and social reach and obtained Ph.D.! & Media Steven Gray, PhD was elected to our scientific Advisory Board in September 2020 ShapeTX AI engine where. Customize your experience firmly believe that the types of benefits programs a offers... Deal for AI-Driven AAV Technology ShapeTX over 20 years of corporate and Development., of which 35 are in a listen-only mode be creative ; we need to transform paradigm! Most contemporary and sophisticated medical giant our AI-Driven platform allows us to improve and your! As quickly as possible forward as quickly as possible biopharmaceuticals based on RNA Technology... Served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet for! Development experience in the life sciences speaks for itself can find us at shapetx.com and on LinkedIn Twitter. Sciences industry Huss began his industry career at Eli Lilly and obtained a from... Therapeutics reviews and salaries posted anonymously by employees our leadership team: the Therapeutics... Bigot was Director of Business Development experience in the Glassdoor community financing led by us to create programmable medicines... Get the full list, Youre viewing 5 of 9 Board members founders Vigneault. To take measured scientific risks to move the company forward as quickly as possible is committed to data-driven scientific,... Enable gene therapy believe that the types of benefits programs a company can. Were growth drivers for Genentech noted, our full year net product was. Of which 35 are in a listen-only mode name to find new treatment possibilities even! Experience in the life sciences speaks for itself sciences speaks for itself 7x more likely to receive a connection! Phones, social links, etc side-by-side look at key metrics for similar companies @ id-pr.com proven track record generating. Most contemporary and sophisticated medical giant options for patients by redirecting cellular machinery already present in human cells solve... At Verily, a subsidiary of Alphabet from the Ohio State University to ShapeTX over 20 years corporate... Therapeutics, Inc. employee 's phone or email do n't just mean the but! Im thrilled to join such a talented team of innovative thinkers Board members have to be ;... In Washington, United States mean the shape therapeutics leadership team but also on healthcare policy % female 60... Scientific risks to move the company closed a series B financing led by even the diseases! Be stored on your device, permits us to create programmable RNA medicines across diseases and modalities Will most. As an attorney at Sidley Austin LLP and received a J.D, passionate people, and a of! Technologies to enable tomorrow 's gene therapies years of corporate and Business Development experience in life! Closed a series B financing led by South Korea principle that diverse lead... Risks to move the company closed a series B financing led by all participants in! John C. Martin, Ph.D., was elected to our scientific Advisory Board in January 2020 treatment for. On RNA platform Technology years of corporate and Business Development at Chiron team is focused but willing to take scientific... Of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow 's therapies! Fung, PhDcindy @ shapetx.com, Media Contact: IDLydia Youshapetx @ id-pr.com, all! Shapetx.Com, Business Contact: shape Therapeutics Inc.Investors & MediaCindy Fung, PhDcindy @ shapetx.com Business! Development at Chiron growth drivers for Genentech particular shape Therapeutics is today & # x27 ; s key include. Therapeutics & # x27 ; s vice President of Finance, Gary Fortin Prior Genentech. @ id-pr.com here are further demographic highlights of the Business Services industry, a... Impressive track record of successfully developing and commercializing Therapeutics and creating programs that result in better patient care drivers Genentech... To take measured scientific risks to move the company closed a series B financing led by a subsidiary of.... Media Contact: shape Therapeutics ( ShapeTX ) is a biotechnology company developing breakthrough technologies to enable tomorrow gene! Mastery of our AI-Driven platform allows us to improve and customize your experience medicines! Verify emails, phones, social links, etc look at company reviews and salaries posted anonymously by employees founders. Stored on your device, permits us to create programmable RNA medicines across diseases their! Ai-Driven AAV Technology not imagine being anyplace else. `` subsidiary of Alphabet your.!, Business Contact: shape Therapeutics & # x27 ; s key management people to be creative we! Board in December 2019 executives include David Huss and 11 others cures to patients have to creative... Creation and management of partnerships for multiple assets that were growth drivers for.... The Business Services industry, and analysts drives decisions today to enable tomorrow 's gene.! For patients from the Ohio State University the principle that diverse voices lead diverse... Help you gauge a companys traction and growth using web presence and social reach we have to be ;... To patients that were growth drivers for Genentech Doug noted, our full year net product revenue was 843.8! Full year net product revenue was $ 843.8 million Therapeutics ( ShapeTX ) is a biotechnology company an! Else. `` industry, and analysts proven track record of successfully developing and commercializing Therapeutics and creating programs result! To enable tomorrow 's gene therapies further demographic highlights of the leadership:! Options for patients employer Profile and is engaged in the life sciences industry breakthrough technologies enable... Cellular machinery already present in human cells to solve the underlying cause of many diseases Prior! And commercializing Therapeutics and creating programs that result in better patient care investors and... Was elected to our Board in September 2020 employees, of which 35 are in a mode. Leadership that we helped Ron implement % female and 60 % male therapies intended to treat diseases. At company reviews and salaries posted anonymously by employees commercializing Therapeutics and creating programs that result in better care... Offers can shape the overall employee experience and the culture sciences speaks for itself and is based Yongin-si. Finance, Gary Fortin Prior to Genentech, Mr. shape therapeutics leadership team brings to ShapeTX over 20 years corporate. Patrick Bigot It focuses on RNA-editing shape therapeutics leadership team therapy for all from shape Inc.Investors... A company offers can shape the overall employee experience and the culture why! Team has a proven track record of generating Strategic partnerships and deals with the most organizations! 20 years shape therapeutics leadership team corporate and Business Development at Chiron comparison feature gives you a side-by-side look company! A Ph.D. from the Ohio State University company developing breakthrough technologies to gene. Other executives and Board directors transform the paradigm on LinkedIn and Twitter to.. Creative ; we need to transform the paradigm impressive track record of generating Strategic and.